Genprex, Inc. (NASDAQ:GNPX) Short Interest Up 430.9% in August

Genprex, Inc. (NASDAQ:GNPX) was the target of a significant increase in short interest in August. As of August 15th, there was short interest totalling 247,400 shares, an increase of 430.9% from the July 31st total of 46,600 shares. Approximately 9.7% of the shares of the stock are short sold. Based on an average daily volume of 231,900 shares, the days-to-cover ratio is presently 1.1 days.

Institutional Trading of Genprex

An institutional investor recently raised its position in Genprex stock. Armistice Capital LLC lifted its position in shares of Genprex, Inc. (NASDAQ:GNPX) by 122.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 218,000 shares of the company’s stock after purchasing an additional 120,132 shares during the period. Armistice Capital LLC owned about 10.39% of Genprex worth $411,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 14.05% of the company’s stock.

Genprex Trading Down 1.0 %

Genprex stock opened at $0.70 on Thursday. Genprex has a 12-month low of $0.56 and a 12-month high of $22.41. The business’s 50-day moving average price is $1.56 and its two-hundred day moving average price is $2.53.

Genprex (NASDAQ:GNPX) last released its earnings results on Friday, August 9th. The company reported ($3.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.30) by ($0.70). As a group, equities research analysts forecast that Genprex will post -5.7 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Genprex in a research report on Wednesday, May 15th.

Genprex Company Profile

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.